

## Contents

Preface IX

Abbreviations and Symbols XIII

<b>1</b>	<b>Physicochemistry</b>	<b>1</b>
1.1	Physicochemistry and Pharmacokinetics	1
1.2	Partition and Distribution Coefficient as Measures of Lipophilicity	2
1.3	Limitations on the Use of 1-Octanol	5
1.4	Further Understanding of Log $P$	6
1.4.1	Unravelling the Principal Contributions to Log $P$	6
1.4.2	Hydrogen Bonding	6
1.4.3	Molecular Size and Shape	8
1.5	Alternative Lipophilicity Scales	10
1.5.1	Different Solvent Systems	10
1.5.2	Chromatographic Approaches	10
1.5.3	Liposome Partitioning	10
1.6	Computational Approaches to Lipophilicity	11
1.7	Membrane Systems to Study Drug Behaviour	12
1.8	Dissolution and Solubility	13
1.8.1	Why Measure Solubility?	13
1.8.2	Calculated Solubility	14
1.9	Ionisation ( $pK_a$ )	15
<b>2</b>	<b>Pharmacokinetics</b>	<b>19</b>
2.1	Setting the Scene	19
2.2	Intravenous Administration: Volume of Distribution	19
2.3	Intravenous Administration: Clearance	20
2.4	Intravenous Administration: Clearance and Half-life	22
2.5	Intravenous Administration: Infusion	23
2.6	Oral Administration	25
2.7	Repeated Doses	26
2.8	Development of the Unbound (Free) Drug Model	28
2.9	Unbound Drug and Drug Action	28

2.10	Unbound Drug Model and Barriers to Equilibrium	31
2.11	Slow Offset Compounds	33
2.12	Factors Governing Unbound Drug Concentration	35
<b>3</b>	<b>Absorption</b>	<b>39</b>
3.1	The Absorption Process	39
3.2	Dissolution	40
3.3	Membrane Transfer	42
3.4	Barriers to Membrane Transfer	46
3.5	Models for Absorption Estimation	49
3.6	Estimation of Absorption Potential	51
3.7	Computational Approaches	51
<b>4</b>	<b>Distribution</b>	<b>55</b>
4.1	Membrane Transfer Access to the Target	55
4.2	Brain Penetration	56
4.3	Volume of Distribution and Duration	59
4.4	Distribution and $T_{\max}$	64
<b>5</b>	<b>Clearance</b>	<b>67</b>
5.1	The Clearance Processes	67
5.2	Role of Transport Proteins in Drug Clearance	68
5.3	Interplay Between Metabolic and Renal Clearance	70
5.4	Role of Lipophilicity in Drug Clearance	71
<b>6</b>	<b>Renal Clearance</b>	<b>83</b>
6.1	Kidney Anatomy and Function	83
6.2	Lipophilicity and Reabsorption by the Kidney	84
6.3	Effect of Charge on Renal Clearance	85
6.4	Plasma Protein Binding and Renal Clearance	85
6.5	Balancing Renal Clearance and Absorption	87
6.6	Renal Clearance and Drug Design	88
<b>7</b>	<b>Metabolic (Hepatic) Clearance</b>	<b>91</b>
7.1	Function of Metabolism (Biotransformation)	91
7.2	Cytochrome P450	92
7.2.1	Catalytic Selectivity of CYP2D6	94
7.2.2	Catalytic Selectivity of CYP2C9	97
7.2.3	Catalytic Selectivity of CYP3A4	98
7.3	Other Oxidative Metabolism Processes	104
7.4	Oxidative Metabolism and Drug Design	107
7.5	Non-Specific Esterases	109
7.5.1	Function of Esterases	109
7.5.2	Ester Drugs as Intravenous and Topical Agents	110
7.6	Prodrugs to Aid Membrane Transfer	111

7.7	Enzymes Catalysing Drug Conjugation	112
7.7.1	Glucuronyl and Sulpho-Transferases	112
7.7.2	Methyl Transferases	115
7.7.3	Glutathione S-Transferases	115
7.8	Stability to Conjugation Processes	116
7.9	Pharmacodynamics and Conjugation	117
<b>8</b>	<b>Toxicity</b>	<b>121</b>
8.1	Toxicity Findings	121
8.1.1	Pharmacophore-induced Toxicity	121
8.1.2	Structure-related Toxicity	123
8.1.3	Metabolism-induced Toxicity	125
8.2	Importance of Dose Size	126
8.3	Epoxides	126
8.4	Quinone Imines	128
8.5	Nitrenium Ions	133
8.6	Iminium Ions	134
8.7	Hydroxylamines	136
8.8	Thiophene Rings	137
8.9	Thioureas	139
8.10	Chloroquinolines	139
8.11	Stratification of Toxicity	140
8.12	Toxicity Prediction: Computational Toxicology	141
8.13	Toxicogenomics	141
8.14	Enzyme Induction (CYP3A4) and Drug Design	142
8.15	Enzyme Inhibition and Drug Design	146
<b>9</b>	<b>Inter-Species Scaling</b>	<b>153</b>
9.1	Objectives of Inter-Species Scaling	153
9.2	Allometric Scaling	153
9.2.1	Volume of Distribution	154
9.2.2	Clearance	156
9.3	Species Scaling: Adjusting for Maximum Life Span Potential	157
9.4	Species Scaling: Incorporating Differences in Metabolic Clearance	158
9.5	Inter-Species Scaling for Clearance by Hepatic Uptake	159
9.6	Elimination Half-Life	161
9.7	Scaling to Pharmacological Effect	161
9.8	Single Animal Scaling	163
<b>10</b>	<b>High(er) Throughput ADME Studies</b>	<b>165</b>
10.1	The High-Throughput Screening (HTS) Trend	165
10.2	Drug Metabolism and Discovery Screening Sequences	165
10.3	Physicochemistry	167
10.3.1	Solubility	168

## VIII | Contents

10.3.2	Lipophilicity	168
10.4	Absorption/Permeability	169
10.5	Pharmacokinetics	169
10.6	Metabolism and Inhibition	170
10.7	The Concept of ADME Space	171
10.8	Computational Approaches in PK and Metabolism	173
10.8.1	QSPR and QSMR	173
10.8.2	PK Predictions Using QSAR and Neural Networks	173
10.8.3	Is <i>In Silico</i> Meeting Medicinal Chemistry Needs in ADME Prediction?	174
10.8.4	Physiologically-Based Pharmacokinetic (PBPK) Modelling	175
10.9	Outlook	175

<b>Index</b>	179
--------------	-----